

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



HANGZHOU TIGERMED CONSULTING CO., LTD.

杭州泰格醫藥科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 3347)

ANNOUNCEMENT IN RELATION TO DEALINGS IN SECURITIES OF A DIRECTOR DURING THE BLACK-OUT PERIOD

This announcement is made by Hangzhou Tigermed Consulting Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to paragraph C.14 of Appendix 10 to the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

On March 14, 2022, the Company was informed by Ms. Cao Xiaochun (“**Ms. Cao**”), an executive director and the general manager of the Company, that 350,000 listed A shares of the Company held by Ms. Cao was pledged as additional collaterals on March 11, 2022 in favour of Huatai Securities Co., Ltd. (华泰证券股份有限公司) (“**Huatai**”) for a loan provided by Huatai to her to facilitate her personal financial arrangements (the “**Pledge**”) as demanded by Huatai as a result of a significant drop of share price of the Company recently.

Pursuant to paragraph A.3 of Appendix 10 to the Listing Rules, the directors of the Company (the “**Directors**”) are prohibited from dealing in any securities of the Company on any day on which its financial results are published and during the period of 60 days immediately preceding the publication date of the annual results (the “**Black-out Period**”). The meeting of the board of Directors (the “**Board**”) for the publication of the annual results for the year ended December 31, 2021 is scheduled on March 28, 2022 and the Pledge therefore fell within the Black-out Period and constituted a dealing of Shares by Ms. Cao. Ms. Cao was in a passive position in relation to the Pledge.

The Directors (except Ms. Cao who is affected by the Pledge), were satisfied that the Pledge during the Black-out Period occurred under exceptional circumstances within the meaning of paragraph C.14 of Appendix 10 to the Listing Rules and should be allowed.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares and other securities of the Company.

By order of the Board
Hangzhou Tigermed Consulting Co., Ltd.
Ye Xiaoping
Chairman

Hong Kong, March 14, 2022

As at the date of this announcement, the executive Directors are Dr. Ye Xiaoping, Ms. Cao Xiaochun, Ms. Yin Zhuan and Mr. Wu Hao; the independent non-executive Directors are Mr. Zheng Bijun, Dr. Yang Bo and Mr. Liu Kai Yu Kenneth.